$VSTS

Vestis Corp

No enriched coverage for $VSTS in the last 7 days.

No SEC Form 4 filings for $VSTS in the last 30 days.

Med

Vestis Corporation (NYSE:VSTS) Just Reported And Analysts Have Been Lifting Their Price Targets

Vestis Corporation (NYSE:VSTS) saw its share price jump 31% after reporting second-quarter results broadly in line with analyst revenue estimates, though EPS forecasts for 2026 were subsequently downgraded. Despite the lowered EPS outlook, analysts increased their price targets by 19% to US$9.30, suggesting long-term value. The company's revenue growth is projected to decline, performing worse than the industry average, yet the price target upgrade indicates a belief in improved intrinsic value over time.

Vestis Faces Legal Scrutiny and Stock Struggles Amid Revenue Forecasts

Vestis Corporation's stock has dropped by 12.87% due to leadership reshuffle concerns and legal scrutiny over allegedly misleading financial guidance. The company faces a challenging fiscal year with modest to negative revenue forecasts, cautious EBITDA predictions, and a high debt-to-equity ratio. Despite some efficient cost management indicated by a 27.4% gross margin, investors remain wary, demanding strategic pivots and fortified corporate ethics to regain trust.